• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
【24h】

Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia

机译：Inotuzumab ozogamicin用于治疗急性淋巴细胞白血病

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Acute lymphoblastic leukemia (ALL) is an uncommon disorder that affects about 20% of adults with acute leukemia. Historically, those who relapse from this condition have a dismal prognosis. Recent developments in immunoconjugate usage has changed the landscape of lymphoid B-cell malignancy therapy. One recent development is the FDA approved therapy inotuzumab ozogamicin which has the potential to reduce the overall toxicity of intensive regimens for ALL, as well as to possibly increase the number of patients who may achieve a state of minimal residual disease.Areas covered: In this review, the pre-clinical and clinical experiences with inotuzumab ozogamicin in lymphoma and ALL are reviewed. The article further includes the published phase I, II and III studies in ALL and considers the safety and efficacy of this treatment.Expert opinion: Inotuzumab ozogamicin is likely to be used, primarily, as a potent agent for relapsed ALL, either as the first choice or for those who fail treatment with blinatumumab. Its potential in newly diagnosed patients is currently unknown, such that the overall impact is likely to be important, but limited.
机译：介绍：急性淋巴细胞白血病（全部）是一种罕见的疾病，可影响急性白血病的20％成年人。从历史上看，那些从这个条件中复发的人预后令人沮丧。 Immunoconjugate使用的最新发展已经改变了淋巴B细胞恶性治疗的景观。最近的一个发展是FDA批准的ozogamicin ozogamicin，有可能降低所有人的整体毒性，以及可能增加可能达到最小残留疾病状态的患者的数量。覆盖：在此综述，综述，患有淋巴瘤中的胰岛替辛替氏菌酸臭氧和所有临床经验。本文还包括出版的I，II和III的研究，并考虑了该治疗的安全性和疗效。普及意见：主要是使用inotuzumab ozogamicin作为重新包装的有效剂，无论是第一选择或与Blinatumumab治疗的人。它在新诊断患者的潜力目前未知，使整体影响可能是重要的，但有限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号